Literature DB >> 24470868

No Evidence of HTLV-II Infection Among Immonoblot Indeterminate Samples Using Nested PCR in Mashhad, Northeast of Iran.

Houshang Rafatpanah1, Farhad Fathimoghadam2, Majid Shahabi3, Iman Eftekharzadeh2, Mohammadreza Hedayati-Moghaddam2, Narges Valizadeh4, Mohsen Tadayon5, Seyyed Aliakbar Shamsian2, Hamidreza Bidkhori2, Raheleh Miri2, Ali Bazarbachi6.   

Abstract

OBJECTIVE(S): Although HTLV-I infection is endemic in different geographical parts of the world including Northeast of Iran, there have been no documents of HTLV-II infection in this region. It is reported that one possible reason for seroindeterminate state in HTLV western blot is HTLV-II virus. This study aimed to investigate the presence of HTLV-II among blood donors with seroindeterminate western blot results.
MATERIALS AND METHODS: Three ml whole blood obtained from 50 blood donors referring to Mashhad Blood Transfusion Organization who had reactive Elisa for HTLV-I and seroindeterminate HTLV western blot state. A conventional PCR was applied to detect HTLV-I provirus using specific primers while a nested PCR was designed with specific external and internal primers for the detection of HTLV-II.
RESULTS: The average age of participants, 39 males and 11 females, was 37.12± 14.36 years. The average OD of the Elisa assay was 1.767± 1.195. The most common indeterminate patterns were Rgp46-II alone (n=12, 27.3%), Rgp46-I alone (n=7, 15.9%), and Rgp46-I with GD21 (n=7, 15.9%).After introducing the DNA to the PCR tests, results revealed 10 (20%) HTLV-I PCR positive samples while no HTLV-II positive sample was detected by nested PCR. There were no significant age, blood group, Optical Density of the Elisa assay, and western blot indeterminate pattern differences between HTLV-I PCR positive and negative samples. Conclusion : No HTLV-II positive sample was detected in this study which confirms the absence of HTLV-II infection in this region. However, high frequency of HTLV-I PCR positive samples among the seroindeterminate cases implies on the important role of molecular techniques for further confirmation of the infection.

Entities:  

Keywords:  HTLV-I; HTLV-II; Iran; Mashhad; PCR; Seroindeterminate; Western blot

Year:  2013        PMID: 24470868      PMCID: PMC3881255     

Source DB:  PubMed          Journal:  Iran J Basic Med Sci        ISSN: 2008-3866            Impact factor:   2.699


Introduction

Human T-Lymphotropic Virus (HTLV) types I and II were the first discovered human retroviruses. HTLV-I was first reported in 1980 while HTLV-II was first reported in 1982 (1-3). HTLV-I is believed to be an etiologic factor for Adult T-cell Leukemia (ATL) and HTLV-I Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) (4-7). However HTLV-II has not been directly connected to any human disease although some recent studies indicate that HTLV-II infection may be associated with two distinct neurologic disorders with similar HAM/TSP symptoms and Tropical Ataxic Neuropathy (TAN) (8-10). HTLV-I is endemic in a number of geographical regions including Japan, Africa, Caribbean islands, South America, and Northeast Iran while the epidemiology of HTLV-II is not well identified (11-15). Within the last decade newly developed serologic assays made us capable to accurately differentiate between antibodies to HTLV-II and HTLV-I. These new techniques include synthetic Enzyme Immunoassays (EIA) (16, 17) and recombinant proteins in a modified Western blot (WB) (18-20). Although such techniques greatly improve the identification and differentiation of HTLV-II from HTLV-I a frequent problem in HTLV-I/II diagnosis which is the high prevalence of indeterminate serological results by WB still leads to difficulties in the interpretation (21). The current diagnosis of HTLV-I and HTLV-II infection is mainly based on Enzyme-linked immunosorbent assays (ELISA) followed by the confirmation of ELISA reactive samples with WB analysis (22). To distinguish HTLV-I from HTLV-II the incorporation of recombinant type-specific glycoprotein rgp46-I or rgp46-II on the WB assay would be employed (22, 23). However some individuals with positive ELISA results show incomplete antibody reactivity to HTLV-I or HTLV-II whom are considered to have indeterminate WB status (24-26). Some recent studies identified HTLV-II proviral DNA in WB indeterminate samples using nested Polymerase Chain Reaction (PCR) analysis (21, 27, 28). Mashhad, located in Northeast of Iran, is an endemic region for HTLV-I infection. It has been recently reported that 2.12% of the general population and 0.77% of blood donors were infected with HTLV-I (15). However no data regarding the situation of HTLV-II infection in this geographical region have been reported yet. Screening of blood donors of Mashhad for HTLV infection which has been mandatory since 1996, is currently based on ELISA assay followed by confirmatory WB analysis (29). To better understand the molecular epidemiology of HTLV infection in this endemic area better, it would be quite beneficial to determine the proportion of HTLV-I/II infection among HTLV-seroindeterminate individuals. The current study aimed to investigate the presence of HTLV-II and HTLV-I infections in Mashhad among WB indeterminate samples from blood donors by nested PCR.

Material and Methods

In this descriptive cross-sectional study blood samples of 50 subjects with WB indeterminate result for HTLV collected from Khorasan Blood Transfusion Organization (BTO), who had donated blood during 2009 and 2010 were selected. Serum samples of all blood donors in Khorasan BTO were routinely tested for HTLV-I/II antibodies using ELISA assay (MP HTLV-I/II ELISA 3.0, MP Diagnostics, Singapore) according to the manufacturer’s instructions and reactive samples were reevaluated in duplicate with the same kit. Repeatedly reactive samples were further evaluated for confirmation of the infection with a WB assay (MP HTLV 2.4 Western blot, MP Diagnostics, Singapore) following the manufacturer’s criteria. According to World Health Organization (WHO) criteria for HTLV seropositivity in WB assay, a sample would be regarded as positive when either gp46 or gp462/68 and one of p19, p24, or p53 were present. The HTLV European Research Network proposed the stringiest criteria for WB seropositivity that defines a WB assay as HTLV-I positive only if bands for the gag proteins p19 and p24 and the env proteins gd21 and MTA-1 were present while it scored as HTLV-II positive if p24, gd21, and K-55 bands were identified and was HTLV positive but nontyped if p24, p19, and gd21 were present (25). In the current study the criteria issued by MP diagnostics HTLV blot 2.4 was employed which is more similar to the HTLV European Research Network criteria. In brief the positive WB for HTLV-I is regarded as the presence of group-specific antigen (gag) proteins (p19 with or without p24) and two envelope (env) proteins (gd21 and rgp46-I) while positive HTLV-II has bands for the gag proteins (p19 with or without p24) and two env proteins (gd21 and rgp46-II). The presence of p24, p19, and gd21 was considered as nontyped HTLV positive. The test was defined as indeterminate if specific bands for HTLV that did not meet the criteria of positivity were present. Besides, those samples that did not show specific bands for HTLV were regarded as negative (Figure 1).
Figure 1

Different WB interpretations among the study samples

Different WB interpretations among the study samples To perform the molecular analysis, 3 ml whole blood was collected in sterile Ethylenediaminetetraacetic acid (EDTA) tubes and genomic DNA was extracted from peripheral blood of WB indeterminate individuals using a commercial DNA extraction kit (QIAmp DNA blood minikit, Qiagen Gmbh, Hilden, Germany) according to the manufacturer’s instructions. Extracted DNA stored at -20 until PCR analysis. In order to confirm HTLV-I infection, Long Terminal Repeat (LTR) and TAX genes were targeted and amplified using designed specific primers (Table 1).
Table 1

Specific primers designed for TAX and LTR regions

NameSequence(5-3)PositionAmplicon (base pair)
TaxfAGGGTTTGGACAGAGTCTT
TaxrAAGGACCTTGAGGGTCTTA7335-7590256 Bp
LTRfCATAAGCTCAGACCTCCGGG
LTRrGGATGGCGGCCTCAGGTAGG8107-8330224 Bp
Specific primers designed for TAX and LTR regions PCR condition for LTR and TAX genes were 10X buffer 2.5 µl, Mgcl2, 2 µl (final concentration of 2 mM), dNTPs 0.5 µl (final concentration 0.2 mM), 0.5µl of each primers (10mM) , 0.5 unit of Taq DNA polymerase enzyme (GENETBIO, Korea) and 50-100 ng DNA. The PCR machine (Astech, JAPAN) was programmed to 94˚C 5min, 35 cycles of 94˚C 45 sec, 60˚C 50 sec, 72˚C 50 sec and a final extension of 72˚C 7min. Amplified products were introduced on 2% gel agarose, stained with ethidium bromide and observed under ultraviolet (UV) luminometer. To determine HTLV-II infection the regions of LTR and TAX genes were selected and amplified using designed specific primers (Table 2).
Table 2

Inner and outer specific primers designed for TAX and LTR regions used in the nested PCR

NameSequence(5’-3’)PositionGenbankAmplicon(Base pair)
First setLTR 2F1LTR 2 R1CTAGCCTCCCAAGCCAGCCACCCCAGTGGTGGGTTGATAGCCC13-878M10060Outer 866 bp
Second setLTR2 F2LTR2 R2CGAGTCATCGACCCAAAAGGTCGGAGTTGGGGAAAGCCCGTGG40-838Inner 799 bp
First settax2 F1tax2 R1TGGATACCCCGTCTACGTGTGAGCTGACAACGCGTCCATCG7248-74060uter 159bp
Second settax2 F2tax2 R2CTACGTGTTTGGCGATTGTGTACTGACAACGCGTCCATCGAT7260-7402Inner 143bp
LTR fragment was amplified by a nested PCR. Briefly a first-round PCR reaction was carried out on 50-100 ng of extracted DNA in a 25 µl reaction mixture containing 0.5 U of Taq DNA polymerase (Genetbio, Korea) 2.5 µl 10x buffer, 2 mM MgCl2, 0.2 mM of each of the Deoxynucleoside triphosphates, and 10 pmol of each outer primer. The PCR cycling conditions consisted of 35 cycles at 95°C for 45 sec, 58°C for 60 sec, and 728C for 180 sec and a final extension of 72˚C for 7min. Inner and outer specific primers designed for TAX and LTR regions used in the nested PCR For the second round 3µl of the first PCR product was used. The PCR mixture was the same as first round PCR but with inner primer set. The PCR machine (Astech, JAPAN) was programmed to 94˚C for 5 min, 35 cycles of 94˚C for 30 sec, 60˚C for 30 sec, 72˚C for 60 sec and a final extension of 72˚C for 7min. A 159 base pair fragment of TAX gene was amplified by the outer primer (Table 2). PCR machine was programmed to 94˚C for 5 min, 35 cycles of 94˚C for 30 sec, 58˚C for 30 sec, 72˚C for 60 sec and a final extension of 72˚C for 7 min. 1 µl of the first PCR product was used for amplification of a 143 base pair fragment using inner primer (Table 2). The PCR machine was programmed to 94˚C for 5min, 35 cycles of 94˚C for 30 sec, 55˚C for 30 sec, 72˚C for 60 sec and a final extension of 72˚C for 7 min. All amplified products were run on 2% gel agarose, stained with ethidium bromide and observed under UV luminometer. The current study is approved by the research deputyship of Iranian Academic Centre for Education, Culture, and Research (ACECR) Mashhad branch regarding ethical and methodological issues. A written consent was obtained from each individual after describing the aims of the study and assuring the participants about the results to be remained anonymous. Demographic data as well as WB and PCR results were registered and analyzed using SPSS V.18.0. Chi-square and Fisher’s exact tests as well as T-test were employed to perform categorical and numerical comparisons respectively. Related tables were produced to discuss the results. P-values <0.05 were considered as statistically significant.

Results

In this study a total 50 WB indeterminate samples were investigated for HTLV-I and HTLV-II proviral DNA using nested PCR. From these 50 participants 39 (78%) were male and 11 (22%) were female. The mean age of participants was 37.12±14.36 years. The most and the least common blood groups were O+ and AB- with 35.4% (n=17) and 0% respectively (Table 3).
Table 3

Frequency of blood groups among WB indeterminate individuals

Blood groupNumber%
A+918.8
B+1633.2
O+1735.4
AB+24.2
A-24.2
B-12.1
O-12.1
AB-00
Frequency of blood groups among WB indeterminate individuals All samples had HTLV-I/II positive reactivity in ELISA. The mean value of Optical Density (OD) in ELISA for the samples was 1.767±1.195. The most common bands in WB were gd21 (47.7%), rgp46-I (38.6%), rgp46-II (31.8%), gp21 (9.1%), p24 (6.8%), p53 (2.3%), and p26 (2.3%) respectively. WB indeterminate patterns were identified for all samples. The most common WB indeterminate patterns were rgp46-II alone (27.3%), rgp46-I alone (15.9%), rgp46-I and gd21 (15.9%), gd21 alone (11.4%), rgp46-I, p24, and gd21 (4.5%), rgp46-II and gd21 (4.5%), p24 and gd21(2.3%), rgp46-I, gd21, and gp21 (2.3%), and p53 alone (2.3%) respectively (Table 4).
Table 4

The frequency of Different WB indeterminate patterns among samples (n=44)

WB indeterminate patternNumber%
Rgp46-I715.9
Rgp46-II1227.3
Rgp46-I,P24,GD2124.5
GP21511.4
Rgp46-I, GD21715.9
GD21613.6
Rgp46-II, GD2124.5
P24, GD2112.3
Rgp46-I, GD21, GP2112.3
P5312.3
The frequency of Different WB indeterminate patterns among samples (n=44) Nested PCR revealed no HTLV-II proviral DNA in samples. However 10 samples (20%) were positive for HTLV-I. From the 10 HTLV-I positive individuals 8 were male (80%) and 2 were female. Also statistical analysis showed no significant difference between HTLV-I PCR positive and negative individuals regarding age, blood group, ELISA OD, and WB indeterminate pattern (P>0.05).

Discussion

The use of PCR enabled scientists to directly detect proviral DNA sequences of HTLV-I and HTLV-II from HTLV infected patients (30, 31). However wide application of PCR was time consuming and expensive which is not suitable for the analysis of large numbers of blood samples (16, 32). Therefore although PCR remained the standard diagnosis of HTLV infection, it is not used as a routine diagnostic tool. Therefore WB assay is used to confirm HTLV-I/II infection in seropositive ELISA samples using recombinant proteins specific for HTLV-I/II env glycoproteins incorporated into WB strips. Such recombinant proteins increase the sensitivity of the assay and enable it to differentiate between HTLV-I and HTLV-II infections. The overall sensitivity and specificity of HTLV WB are reported as 97.1% and 97.5% respectively (33). By the wide utilization of WB assay for HTLV confirmation WB indeterminate results became a global problem for blood banks specially in endemic areas (29). Several possible explanations have been proposed for the occurrence of HTLV WB indeterminate states. The most accepted explanations include cross reacting to other known retroviruses like Simian T-Cell Leukemia Virus (STLV) or HTLV-I related endogenous sequence (HRES-I) or a novel virus, antibody responses to a malaria parasite with epitope homology to HTLV-II like Plasmodium Falciparum, a defective HTLV-I or HTLV-II, and low copy numbers of prototype HTLV-I in the affected patient having indeterminate state (33). To better understand the status of HTLV-I and HTLV-II infections in WB indeterminate samples we investigate 50 indeterminate samples from Mashhad blood donors. The current study results demonstrate a high rate of HTLV-I infection among WB indeterminate samples (20%) using PCR technique that may be due to low copy number of prototype HTLV-I. Similar results reported by previous studies indicated the ability to amplify HTLV-I tax region from PBMCs of some HTLV WB indeterminate individuals (26, 34). Moreover the current study results showed that the previous hypothesis that HTLV WB indeterminate samples could be considered as negative is wrong. Presence of 20% HTLV-I positivity among indeterminate WB samples displays a relatively high rate and emphasizes the importance of molecular investigations to detect HTLV as well as the importance of determining the exact status of WB indeterminate individuals to better control the infection. Similar results with various frequencies were reported by Costa and Segurado in Brazil, Mangano et al in Argentina, Berini et al in Argentina, and Santos et al in Brazil with 9.2%, 13.8%, 13.2%, and 22% frequencies respectively (21, 27, 28, 35). Similar to other studies performed on WB indeterminate samples, the current study observed no significant difference regarding age, gender, and blood group of HTLV-I PCR positive and negative individuals (35, 36). Nested PCR results showed no evidence of HTLV-II infection among indeterminate WB individuals in the present study which was predictable due to no previous reports of HTLV-II in this region (12, 15). Similar studies in other geographical regions especially South America revealed some cases of HTLV-II among WB indeterminate individuals (21, 27, 28, 37). The most common indeterminate patterns in the current study were single bands of rgp46-II, rgp46-I, and gd21 which were similar to the findings of Mangano et al but in contrast to the findings of Rouet et al and Costa and Segurado (25, 27, 28).

Conclusion

The results of the current study revealed a high rate of HTLV-I infection among WB indeterminate samples as well as no HTLV-II infection. Therefore it can be concluded that HTLV-II is not a matter of concern in this region while special attention to indeterminate WB individuals regarding HTLV-I infection is necessary. It is recommended to determine the status of HTLV-I infection in WB indeterminate blood donors in Northeast of Iran using molecular techniques such as PCR to control the infection.
  36 in total

1.  HTLV-I/II seroindeterminate Western blot reactivity in a cohort of patients with neurological disease.

Authors:  S S Soldan; M D Graf; A Waziri; A N Flerlage; S M Robinson; T Kawanishi; T P Leist; T J Lehky; M C Levin; S Jacobson
Journal:  J Infect Dis       Date:  1999-09       Impact factor: 5.226

2.  Molecular analysis of human T cell lymphotropic virus type 1 and 2 (HTLV-1/2) seroindeterminate blood donors from Northeast Iran: evidence of proviral tax, env, and gag sequences.

Authors:  Delaram Sayadpour Zanjani; Majid Shahabi; Nasim Talaei; Monavar Afzalaghaee; Farahnaz Tehranian; Reihane Bazargani
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-07       Impact factor: 2.205

3.  Use of a generic polymerase chain reaction assay detecting human T-lymphotropic virus (HTLV) types I, II and divergent simian strains in the evaluation of individuals with indeterminate HTLV serology.

Authors:  A M Vandamme; K Van Laethem; H F Liu; M Van Brussel; E Delaporte; C M de Castro Costa; C Fleischer; G Taylor; U Bertazzoni; J Desmyter; P Goubau
Journal:  J Med Virol       Date:  1997-05       Impact factor: 2.327

4.  Primary isolation of human T-cell leukemia-lymphoma virus types I and II: use for confirming infection in seroindeterminate blood donors.

Authors:  B Hjelle; R Mills; C Goldsmith; S G Swenson; S Cyrus
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

Review 5.  Epidemiologic features of HTLV-II: serologic and molecular evidence.

Authors:  George W Lowis; William A Sheremata; Alireza Minagar
Journal:  Ann Epidemiol       Date:  2002-01       Impact factor: 3.797

6.  Association of '(tropical) ataxic neuropathy' with HTLV-II.

Authors:  W A Sheremata; W J Harrington; P A Bradshaw; S K Foung; S P Raffanti; J R Berger; S Snodgrass; L Resnick; B J Poiesz
Journal:  Virus Res       Date:  1993-07       Impact factor: 3.303

7.  Isolation of HTLV-II from a patient with chronic, progressive neurological disease clinically indistinguishable from HTLV-I-associated myelopathy/tropical spastic paraparesis.

Authors:  S Jacobson; T Lehky; M Nishimura; S Robinson; D E McFarlin; S Dhib-Jalbut
Journal:  Ann Neurol       Date:  1993-04       Impact factor: 10.422

Review 8.  Human T-lymphotropic virus type II and neurological disease.

Authors:  Abelardo Araujo; William W Hall
Journal:  Ann Neurol       Date:  2004-07       Impact factor: 10.422

9.  Modified Western blot assay for confirmation and differentiation of human T cell lymphotropic virus types I and II.

Authors:  J J Lipka; P Santiago; L Chan; G R Reyes; K P Samuel; W A Blattner; G M Shaw; C V Hanson; J J Sninsky; S K Foung
Journal:  J Infect Dis       Date:  1991-08       Impact factor: 5.226

10.  Epidemiology of HTLV-1 in Neyshabour, Northeast of Iran.

Authors:  M R Hedayati-Moghaddam; F Fathimoghadam; I Eftekharzadeh Mashhadi; L Soghandi; H R Bidkhori
Journal:  Iran Red Crescent Med J       Date:  2011-06-01       Impact factor: 0.611

View more
  3 in total

Review 1.  Updates on the Epidemiology of the Human T-Cell Leukemia Virus Type 1 Infection in the Countries of the Eastern Mediterranean Regional Office of the World Health Organization with Special Emphasis on the Situation in Iran.

Authors:  Mohammad Reza Hedayati-Moghaddam; Reza Jafarzadeh Esfehani; Hiba El Hajj; Ali Bazarbachi
Journal:  Viruses       Date:  2022-03-23       Impact factor: 5.818

2.  Seroepidemiology of HTLV-1 and HTLV-2 Infection in Neyshabur City, North-Eastern Iran, during 2010-2014.

Authors:  Mohammad Salehi; Seyyed Khalil Shokouhi Mostafavi; Abdolmajid Ghasemian; Mahmoud Gholami; Abdolrahim Kazemi-Vardanjani; Mohammad Karim Rahimi
Journal:  Iran Biomed J       Date:  2016-07-05

3.  Prevalence of CCR5delta32 in Northeastern Iran.

Authors:  Amir Tajbakhsh; Mostafa Fazeli; Mehdi Rezaee; Faezeh Ghasemi; Mastoureh Momen Heravi; Aida Gholoobi; Zahra Meshkat
Journal:  BMC Med Genet       Date:  2019-11-15       Impact factor: 2.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.